DOCM — DocMorris AG Share Price
- CH₣246.26m
- CH₣474.17m
- CH₣1.02bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.72 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.24 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -13.5% | ||
Return on Equity | -25.24% | ||
Operating Margin | -8.78% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CH₣m | 1,476.93 | 1,726.5 | 930.97 | 969.46 | 1,017.04 | 1,165.89 | 1,376.28 | -5.58% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
DocMorris AG, formerly Zur Rose Group AG, is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. DocMorris operates at the healthcare, technology and e-commerce, with a primary focus on customer-centric digital healthcare and improving medication efficacy. core business is online pharmacy. In addition to prescription medicines (Rx), assortment features over-the-counter (OTC) and consumer health as well as beauty and personal care (BPC) products. Private labels, including nutritional supplements, painkillers, first-aid products and other OTC medicines. The Company's operates under brands such as PromoFarma, DoctiPharma, Apotal, Medpex and Teleclinic, among others
Directors
- Walter Oberhaensli CMG (63)
- Stefan Feuerstein NEC (65)
- Thomas Schneider NVC (66)
- Marcel Ziwica CFO (46)
- Bernd Gschaider COO (55)
- Walter Hess MGB (56)
- Emanuel Lorini MGB (44)
- David Maso MGB (50)
- Betul Unaran MGB (45)
- Volker Amelung NED (56)
- Tobias Hartmann NED (49)
- Christian Mielsch NED (59)
- Florian Seubert NED (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 6th, 1993
- Public Since
- July 6th, 2017
- No. of Shareholders
- 14,270
- No. of Employees
- 1,454
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
SIX Swiss Exchange
- Shares in Issue
- 11,816,512

- Address
- Walzmuehlestrasse 49, FRAUENFELD, 8500
- Web
- https://corporate.docmorris.com/en/
- Phone
- +41 527240020
- Contact
- Daniel Grigat
- Auditors
- Ernst & Young Ltd
Upcoming Events for DOCM
DocMorris AG at UBS Best of Europe Virtual One-on-One Conference
DocMorris AG at Stifel Swiss Equities Conference
Half Year 2025 DocMorris AG Earnings Release
Half Year 2025 DocMorris AG Earnings Call
DocMorris AG at Baader Investment Conference
Q3 2025 DocMorris AG Trading Statement Release
Similar to DOCM
Villars Holding SA
SIX Swiss Exchange
FAQ
As of Today at 20:17 UTC, shares in DocMorris AG are trading at CH₣20.84. This share price information is delayed by 15 minutes.
Shares in DocMorris AG last closed at CH₣20.84 and the price had moved by -74.78% over the past 365 days. In terms of relative price strength the DocMorris AG share price has underperformed the FTSE Global All Cap Index by -75.41% over the past year.
The overall consensus recommendation for DocMorris AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDocMorris AG does not currently pay a dividend.
DocMorris AG does not currently pay a dividend.
DocMorris AG does not currently pay a dividend.
To buy shares in DocMorris AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣20.84, shares in DocMorris AG had a market capitalisation of CH₣246.26m.
Here are the trading details for DocMorris AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: DOCM
Based on an overall assessment of its quality, value and momentum DocMorris AG is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in DocMorris AG is CH₣28.40. That is 36.28% above the last closing price of CH₣20.84.
Analysts covering DocMorris AG currently have a consensus Earnings Per Share (EPS) forecast of -CH₣6.89 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DocMorris AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -42.66%.
As of the last closing price of CH₣20.84, shares in DocMorris AG were trading -29.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DocMorris AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣20.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
DocMorris AG's management team is headed by:
- Walter Oberhaensli - CMG
- Stefan Feuerstein - NEC
- Thomas Schneider - NVC
- Marcel Ziwica - CFO
- Bernd Gschaider - COO
- Walter Hess - MGB
- Emanuel Lorini - MGB
- David Maso - MGB
- Betul Unaran - MGB
- Volker Amelung - NED
- Tobias Hartmann - NED
- Christian Mielsch - NED
- Florian Seubert - NED